AIM To observe the clinical efficacy and safety of thrombolytic therapy using recombinant prourokinase (rhPro-UK) in patients with acute myocardial infarction with ST-segment elvation (STEMI).
METHODS STEMI patients with thrombolysis were selected and were divided into recombinant prourokinase group (n=206) and urokinase group (n=92). Baseline data of the two groups were collected, and clinical coronary recanalization rate, coronary angiography TIMI≥2 opening rate, major bleeding events and complication rate were compared between the two groups.
RESULTS Compared with those in urokinase group, the clinical recanalization rate 164 (79.62%) vs. 52 (63.04%), P<0.01 and the opening rate of TIM≥2 149 (82.78%) vs. 50 (65.79%), P<0.01 were significantly improved in recombinant prourokinase group, while the major bleeding events 15 (7.8%) vs. 14(15.22%), P<0.05 and the complication rate 5 (2.3%) vs. 8 (8.70%), P<0.05 were significant reduced.
CONCLUSION Recombinant prourokinase has a higher rate of thrombolytic vascular recanalization and a lower incidence of bleeding events and complications.
DownLoad: